ATE170082T1 - Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen - Google Patents
Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilenInfo
- Publication number
- ATE170082T1 ATE170082T1 AT95117465T AT95117465T ATE170082T1 AT E170082 T1 ATE170082 T1 AT E170082T1 AT 95117465 T AT95117465 T AT 95117465T AT 95117465 T AT95117465 T AT 95117465T AT E170082 T1 ATE170082 T1 AT E170082T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- growth
- inhibiting
- cells
- leukemic cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33760594A | 1994-11-10 | 1994-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE170082T1 true ATE170082T1 (de) | 1998-09-15 |
Family
ID=23321225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95117465T ATE170082T1 (de) | 1994-11-10 | 1995-11-07 | Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0711565B1 (de) |
AT (1) | ATE170082T1 (de) |
DE (1) | DE69504278T2 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
US6627196B1 (en) | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
WO2001021192A2 (en) * | 1999-09-22 | 2001-03-29 | Corixa Corporation | Methods for diagnosis and therapy of hematological and virus-associated malignancies |
ATE441433T1 (de) | 2000-05-19 | 2009-09-15 | Genentech Inc | Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten |
WO2002013847A2 (en) * | 2000-08-14 | 2002-02-21 | Corixa Corporation | Methods for diagnosis and therapy of hematological and virus-associated malignancies |
ZA200706017B (en) | 2005-01-21 | 2008-12-31 | Genentech Inc | Fixed dosing of her antibodies |
EP1850874B1 (de) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Verzögerung des krankheitsverlauf bei eierstockkrebspatienten durch pertuzumab |
MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
ES2417148T3 (es) | 2007-06-08 | 2013-08-06 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
US8734795B2 (en) | 2008-10-31 | 2014-05-27 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
TWI461211B (zh) | 2009-03-20 | 2014-11-21 | Genentech Inc | 抗-her抗體 |
EP2435071A1 (de) | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulatoren für den her2-signalweg bei her2-exprimierenden patienten mit magenkrebs |
EP2536748B1 (de) | 2010-02-18 | 2014-08-20 | Genentech, Inc. | Neuregulin-antagonisten und ihre verwendung zur behandlung von krebs |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2643353A1 (de) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispezifische moleküle |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
JP2014526891A (ja) | 2011-08-17 | 2014-10-09 | ジェネンテック, インコーポレイテッド | ニューレグリン抗体とその使用 |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
RU2019103083A (ru) | 2011-11-30 | 2019-03-22 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
US20130259867A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
-
1995
- 1995-11-07 DE DE69504278T patent/DE69504278T2/de not_active Expired - Fee Related
- 1995-11-07 EP EP95117465A patent/EP0711565B1/de not_active Expired - Lifetime
- 1995-11-07 AT AT95117465T patent/ATE170082T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69504278T2 (de) | 1999-05-06 |
DE69504278D1 (de) | 1998-10-01 |
EP0711565A1 (de) | 1996-05-15 |
EP0711565B1 (de) | 1998-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE170082T1 (de) | Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen | |
DE60330390D1 (de) | G-csf zur behandlung von amyotropher lateralsklerose | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
DE69508192D1 (de) | Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen | |
ATE402698T1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
TW200502385A (en) | Modulation of forkhead box o1a expression | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
DE69809898D1 (de) | Zusammensetzung und verfahren zur behandlung von pflanzen mit exogenen chemikalien | |
ATE465261T1 (de) | Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken | |
DE69622989D1 (de) | Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten | |
ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
DE69619187D1 (de) | Verfahren zur behandlung von motorischen defiziten | |
ATE331799T1 (de) | Verfahren zur inhibierung der transkription von genen | |
DE60111620D1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
ATE288498T1 (de) | Methoden zur inhibierung von helicobacter pylori | |
ATE203162T1 (de) | Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one | |
ATE325812T1 (de) | Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors | |
ATE438859T1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
ATE320263T1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie | |
ATE269090T1 (de) | Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv | |
ATE311901T1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
DE69903931D1 (de) | Vorrichtung zur behandlung von wasser | |
DE69936234D1 (de) | Verfahren und Zusammenstzung zur Hemmung des Wachtums von neoplastischen Zellen | |
WO2004043353A3 (en) | Compositions and methods for treating acute myeloid leukemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |